TFG is an inclusion criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains TFG status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [4].

TFG is altered in 0.12% of lymphoma patients [3].

TFG is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TFG status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TFG is altered in 0.21% of malignant solid tumor patients [3].

TFG is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains TFG status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

TFG is altered in 0.96% of poorly differentiated thyroid gland carcinoma patients [3].

TFG is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TFG status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TFG is an inclusion criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TFG status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TFG is altered in 0.35% of thyroid gland papillary carcinoma patients [3].

TFG is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TFG status and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TFG is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TFG status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].